Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Prostate cancer (mmu05215)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Ar
KLA  ATP  ATP+KLA
 NM_013476 androgen receptor (Ar), mRNA [NM_013476] KLA 1.00 1.02 1.01 1.02 1.00 .99 1.01
ATP 1.00 1.00 1.01 1.00 1.01 1.00 1.01
KLA/ATP .99 .99 1.00 1.02 1.00 1.00 .99
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Atf4
KLA  ATP  ATP+KLA
 NM_009716 activating transcription factor 4 (Atf4), mRNA [NM_009716] KLA .91 1.06 1.13 1.31 1.92 2.59 3.01
ATP 1.05 1.14 1.34 2.88 4.84 2.36 2.56
KLA/ATP 1.14 1.08 1.17 2.40 3.72 3.54 3.62
Bad
KLA  ATP  ATP+KLA
 AK029400 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] KLA 1.15 1.22 1.26 1.31 1.40 1.67 1.59
ATP .95 1.06 1.12 1.06 .78 .89 1.27
KLA/ATP 1.25 1.39 1.33 1.29 1.11 .91 1.38
Bcl2
KLA  ATP  ATP+KLA
 NM_009741 B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] KLA .30 .26 .25 .25 .34 .38 .26
ATP .97 .89 1.50 1.04 .99 .29 .52
KLA/ATP .28 .26 .40 .33 .62 .29 .12
Bcl2
KLA  ATP  ATP+KLA
 NM_177410 B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] KLA .33 .33 .37 .42 .49 .46 .39
ATP 1.07 1.12 1.22 1.56 1.00 .38 .76
KLA/ATP .35 .34 .54 .89 .76 .36 .23
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Casp9
KLA  ATP  ATP+KLA
 NM_015733 caspase 9 (Casp9), mRNA [NM_015733] KLA .31 .31 .40 .66 .89 1.19 .91
ATP .88 .77 .91 .59 .43 .75 .93
KLA/ATP .26 .26 .30 .28 .80 1.06 .97
Ccnd1
KLA  ATP  ATP+KLA
 S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Ccne1
KLA  ATP  ATP+KLA
 NM_007633 cyclin E1 (Ccne1), mRNA [NM_007633] KLA 1.13 1.14 1.13 .78 .51 .69 .55
ATP .92 .94 1.09 .93 .75 .71 .47
KLA/ATP 1.13 1.17 1.45 1.24 1.33 1.50 .85
Ccne2
KLA  ATP  ATP+KLA
 NM_001037134 cyclin E2 (Ccne2), transcript variant 1, mRNA [NM_001037134] KLA .34 .35 .42 .36 .35 .36 .26
ATP 1.02 1.11 1.01 .82 .58 .38 .23
KLA/ATP .36 .34 .44 .43 .41 .40 .25
Cdk2
KLA  ATP  ATP+KLA
 NM_016756 cyclin-dependent kinase 2 (Cdk2), transcript variant 2, mRNA [NM_016756] KLA .68 .67 .62 .63 .60 .74 .73
ATP 1.02 1.14 .91 .92 .68 .71 .65
KLA/ATP .67 .64 .64 .64 .61 .74 .62
Cdkn1a
KLA  ATP  ATP+KLA
 NM_007669 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] KLA 4.72 4.90 4.96 3.73 2.11 1.14 1.02
ATP 1.14 1.52 .95 1.69 1.47 2.21 .50
KLA/ATP 5.99 7.08 3.86 6.37 3.00 2.55 2.05
Cdkn1b
KLA  ATP  ATP+KLA
 NM_009875 cyclin-dependent kinase inhibitor 1B (Cdkn1b), mRNA [NM_009875] KLA .81 .84 .84 .91 .93 .88 .97
ATP .99 1.09 .97 1.06 1.48 .94 .91
KLA/ATP .83 .91 1.04 1.36 1.48 1.06 1.09
Chuk
KLA  ATP  ATP+KLA
 NM_007700 conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] KLA 1.32 1.42 1.41 1.17 1.32 1.22 1.40
ATP 1.22 1.30 1.18 .97 1.02 1.00 1.37
KLA/ATP 1.56 1.61 1.21 1.09 .83 .84 1.17
Creb1
KLA  ATP  ATP+KLA
 NM_009952 cAMP responsive element binding protein 1 (Creb1), transcript variant B, mRNA [NM_009952] KLA 1.42 1.33 1.16 .99 .83 .97 .92
ATP .92 .91 1.18 1.38 1.51 1.02 .75
KLA/ATP 1.34 1.31 1.49 1.37 1.71 1.05 .93
Creb3
KLA  ATP  ATP+KLA
 NM_013497 cAMP responsive element binding protein 3 (Creb3), mRNA [NM_013497] KLA 1.21 1.21 1.23 1.53 1.77 1.77 1.31
ATP 1.02 1.03 .99 1.05 .82 .83 1.48
KLA/ATP 1.15 1.18 1.20 1.26 1.13 1.15 1.86
Creb3l1
KLA  ATP  ATP+KLA
 NM_011957 cAMP responsive element binding protein 3-like 1 (Creb3l1), mRNA [NM_011957] KLA 1.18 1.17 1.53 1.28 1.22 1.11 1.23
ATP 1.01 1.09 .98 1.17 1.22 1.01 1.15
KLA/ATP 1.22 1.29 1.08 1.34 1.14 1.36 1.12
Creb3l2
KLA  ATP  ATP+KLA
 AK082964 12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530025K05 product:unclassifiable, full insert sequence [AK082964] KLA .44 .38 .37 .40 .45 .42 .47
ATP .90 .78 1.22 .79 .54 .46 .44
KLA/ATP .41 .41 .49 .43 .50 .51 .23
Creb3l2
KLA  ATP  ATP+KLA
 NM_178661 cAMP responsive element binding protein 3-like 2 (Creb3l2), mRNA [NM_178661] KLA .98 .87 .76 .98 1.03 .87 1.12
ATP 1.20 1.18 1.50 1.35 .86 1.32 1.50
KLA/ATP .98 1.04 1.15 1.05 .79 1.27 1.25
Creb3l3
KLA  ATP  ATP+KLA
 NM_145365 cAMP responsive element binding protein 3-like 3 (Creb3l3), mRNA [NM_145365] KLA .66 .75 .65 .85 1.04 1.44 1.73
ATP 1.02 .98 .97 1.09 .85 .69 1.11
KLA/ATP .70 .66 .71 .83 .80 .85 1.05
Creb3l4
KLA  ATP  ATP+KLA
 NM_030080 cAMP responsive element binding protein 3-like 4 (Creb3l4), mRNA [NM_030080] KLA 1.55 1.42 1.51 1.73 1.76 2.54 1.38
ATP 1.07 .81 .89 1.08 .94 1.08 1.08
KLA/ATP 1.44 1.38 1.44 1.25 1.30 1.26 2.24
Creb5
KLA  ATP  ATP+KLA
 AK051306 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130032G03 product:unclassifiable, full insert sequence. [AK051306] KLA 2.18 2.13 2.42 1.97 1.57 1.94 1.98
ATP 1.11 1.09 1.47 1.74 1.36 1.44 1.62
KLA/ATP 2.55 2.77 3.02 3.15 2.51 2.52 2.61
Creb5
KLA  ATP  ATP+KLA
 NM_172728 cAMP responsive element binding protein 5 (Creb5), mRNA [NM_172728] KLA 3.70 3.60 2.84 2.39 1.92 2.81 1.84
ATP .92 .89 1.19 1.93 1.51 1.55 1.44
KLA/ATP 3.16 3.51 4.33 5.35 5.78 3.23 3.03
Crebbp
KLA  ATP  ATP+KLA
 AK048818 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230072N21 product:hypothetical protein, full insert sequence [AK048818] KLA 1.44 1.19 1.26 1.25 1.25 1.36 1.24
ATP .98 .90 1.04 1.11 1.95 2.72 1.51
KLA/ATP 1.17 1.27 1.45 1.28 1.98 2.80 2.52
Crebbp
KLA  ATP  ATP+KLA
 NM_001025432 CREB binding protein (Crebbp), mRNA [NM_001025432] KLA .97 1.01 .98 1.06 1.05 .99 1.07
ATP 1.07 1.05 .96 1.01 1.15 1.14 1.00
KLA/ATP 1.01 .97 .97 1.00 1.03 1.23 1.13
Crebbp
KLA  ATP  ATP+KLA
 S66385 gb|CREB-binding protein [mice, brain, mRNA Partial, 7326 nt]. [S66385] KLA 1.00 .98 1.08 .98 1.04 1.07 1.08
ATP .99 .98 .99 1.09 1.13 1.08 1.05
KLA/ATP 1.06 1.00 1.05 1.03 1.02 1.14 1.11
Ctnnb1
KLA  ATP  ATP+KLA
 AK020013 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830416C23 product:catenin beta, full insert sequence. [AK020013] KLA 1.06 1.15 1.00 1.06 1.27 1.14 1.03
ATP .85 .57 1.74 3.36 4.13 2.19 1.55
KLA/ATP 1.12 .87 2.47 3.61 3.79 2.21 2.06
Ctnnb1
KLA  ATP  ATP+KLA
 NM_007614 catenin (cadherin associated protein), beta 1 (Ctnnb1), mRNA [NM_007614] KLA 1.02 1.07 1.13 1.03 1.04 .93 .96
ATP 1.12 1.14 .75 .77 .73 .72 1.52
KLA/ATP 1.18 1.17 .77 .85 .60 .59 1.35
E2f1
KLA  ATP  ATP+KLA
 NM_007891 E2F transcription factor 1 (E2f1), mRNA [NM_007891] KLA .41 .44 .42 .41 .48 .77 .90
ATP 1.01 1.09 1.04 1.13 .83 .53 .84
KLA/ATP .44 .44 .52 .50 .49 .46 .85
E2f2
KLA  ATP  ATP+KLA
 NM_177733 E2F transcription factor 2 (E2f2), mRNA [NM_177733] KLA .13 .13 .14 .20 .19 .19 .18
ATP 1.08 .92 1.01 .85 .65 .38 .38
KLA/ATP .13 .13 .21 .20 .32 .24 .26
E2f3
KLA  ATP  ATP+KLA
 AK085296 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630007K21 product:E2F transcription factor 3, full insert sequence. [AK085296] KLA .98 .97 1.02 1.00 .99 .99 .99
ATP .97 1.06 1.03 .98 1.01 .99 1.00
KLA/ATP 1.12 1.14 1.03 .99 .96 .93 .96
E2f3
KLA  ATP  ATP+KLA
 NM_010093 E2F transcription factor 3 (E2f3), mRNA [NM_010093] KLA 1.11 1.09 1.13 1.21 1.47 1.62 1.65
ATP .97 .98 1.08 1.15 1.45 1.73 1.80
KLA/ATP 1.21 1.13 1.07 1.20 1.45 1.56 1.62
Egf
KLA  ATP  ATP+KLA
 NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Ep300
KLA  ATP  ATP+KLA
 AK042627 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730011L11 product:P300 TRANSCRIPTION COACTIVATOR (FRAGMENT) homolog [Mus sp], full insert sequence. [AK042627] KLA 1.02 .95 .92 1.04 1.01 1.00 1.05
ATP 1.06 .89 .88 .89 1.00 .90 1.07
KLA/ATP 1.10 1.02 .87 .91 1.04 .97 .98
Ep300
KLA  ATP  ATP+KLA
 NM_177821 E1A binding protein p300 (Ep300), mRNA [NM_177821] KLA 1.61 1.26 1.57 1.38 1.78 1.41 1.40
ATP 1.34 1.60 1.11 1.08 1.16 1.05 1.15
KLA/ATP 1.86 1.94 1.18 1.56 1.71 1.42 2.05
Erbb2
KLA  ATP  ATP+KLA
 NM_001003817 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] KLA 1.01 1.00 .98 1.01 .98 .99 .97
ATP .99 1.00 1.00 1.00 .96 .98 .99
KLA/ATP 1.00 1.01 1.01 1.02 .96 .98 .97
Fgfr1
KLA  ATP  ATP+KLA
 M28998 gb|Mouse basic fibroblast growth factor receptor (bFGF-R) mRNA, complete cds. [M28998] KLA .82 .79 .73 .66 .50 .55 .65
ATP 1.01 1.08 .86 .90 1.29 1.24 1.52
KLA/ATP .85 .82 .71 .71 .63 .80 .85
Fgfr1
KLA  ATP  ATP+KLA
 NM_010206 fibroblast growth factor receptor 1 (Fgfr1), transcript variant 1, mRNA [NM_010206] KLA .92 .86 .73 .82 .79 .85 .84
ATP 1.01 1.06 .92 .92 1.18 1.02 1.22
KLA/ATP .83 .83 .79 .76 .83 .83 .92
Fgfr2
KLA  ATP  ATP+KLA
 NM_010207 fibroblast growth factor receptor 2 (Fgfr2), transcript variant 1, mRNA [NM_010207] KLA 1.01 .98 1.00 1.01 .98 1.00 .99
ATP 1.00 1.03 1.05 1.03 1.01 1.01 1.00
KLA/ATP 1.00 1.01 1.04 1.01 .99 1.02 1.03
Foxo1
KLA  ATP  ATP+KLA
 NM_019739 forkhead box O1 (Foxo1), mRNA [NM_019739] KLA .60 .55 .60 .58 .49 .60 .71
ATP .96 1.03 1.08 1.03 2.49 1.70 .98
KLA/ATP .56 .58 .67 .83 1.47 1.57 .97
Frap1
KLA  ATP  ATP+KLA
 NM_020009 FK506 binding protein 12-rapamycin associated protein 1 (Frap1), mRNA [NM_020009] KLA 1.37 1.32 1.46 1.57 1.83 1.29 1.28
ATP 1.12 1.07 .95 .91 .80 .77 1.03
KLA/ATP 1.45 1.51 1.50 1.11 .89 .87 1.01
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
Gstp1
KLA  ATP  ATP+KLA
 NM_013541 glutathione S-transferase, pi 1 (Gstp1), mRNA [NM_013541] KLA .99 .99 .98 .92 .92 .79 .85
ATP 1.06 1.10 1.06 1.27 1.13 1.62 2.31
KLA/ATP .98 1.02 1.03 1.22 1.02 1.25 2.47
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Hsp90aa1
KLA  ATP  ATP+KLA
 NM_010480 heat shock protein 90, alpha (cytosolic), class A member 1 (Hsp90aa1), mRNA [NM_010480] KLA .95 1.03 .90 .92 .80 .94 .99
ATP .96 .92 1.39 1.21 2.02 3.66 1.10
KLA/ATP .93 .92 1.32 1.01 1.85 2.21 1.20
Hsp90ab1
KLA  ATP  ATP+KLA
 NM_008302 heat shock protein 90kDa alpha (cytosolic), class B member 1 (Hsp90ab1), mRNA [NM_008302] KLA .93 1.02 .98 .82 .95 1.10 1.39
ATP 1.04 1.14 .92 1.32 1.19 1.02 .63
KLA/ATP 1.02 1.04 .80 1.12 .87 .86 .75
Hsp90b1
KLA  ATP  ATP+KLA
 NM_011631 heat shock protein 90, beta (Grp94), member 1 (Hsp90b1), mRNA [NM_011631] KLA .78 .83 .71 .69 .73 .69 .80
ATP 1.00 1.08 1.01 .94 .84 .84 .66
KLA/ATP .78 .82 .81 .73 .66 .68 .27
Igf1
KLA  ATP  ATP+KLA
 AK050118 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] KLA .13 .14 .15 .16 .22 .34 .48
ATP 1.78 2.05 1.37 .72 .34 .41 .58
KLA/ATP .24 .45 .50 .24 .20 .26 .68
Igf1
KLA  ATP  ATP+KLA
 NM_010512 insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] KLA .84 .78 .76 .67 .54 .48 .59
ATP .97 .98 1.13 1.13 1.03 .88 .89
KLA/ATP .82 .81 .93 .86 .83 .65 .89
Igf1
KLA  ATP  ATP+KLA
 NM_184052 insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] KLA .77 .82 .76 .65 .60 .52 .69
ATP 1.01 1.07 .98 1.06 1.03 .78 .94
KLA/ATP .89 .86 .77 .80 .75 .65 .89
Igf1r
KLA  ATP  ATP+KLA
 NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Ikbkb
KLA  ATP  ATP+KLA
 NM_010546 inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] KLA 1.88 2.10 2.14 1.83 1.73 1.31 1.19
ATP .81 .74 .55 .49 .59 1.05 .96
KLA/ATP 1.86 1.73 1.39 1.12 .89 1.17 1.24
Ikbkg
KLA  ATP  ATP+KLA
 AK042138 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] KLA .92 .87 .78 .78 .87 .88 .62
ATP .84 .71 .80 .50 1.15 2.33 .61
KLA/ATP .72 .69 .74 .48 1.06 1.97 .68
Ikbkg
KLA  ATP  ATP+KLA
 NM_010547 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] KLA 1.51 1.63 1.74 1.83 1.83 1.73 1.72
ATP .80 .79 .82 .75 .66 2.58 2.37
KLA/ATP 1.43 1.42 1.17 1.04 .71 1.54 3.17
Ikbkg
KLA  ATP  ATP+KLA
 NM_178590 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] KLA .84 .93 .86 .91 1.03 .89 .88
ATP 1.03 .98 .68 .56 .51 .93 .68
KLA/ATP .89 .81 .55 .52 .41 .67 .65
Ins1
KLA  ATP  ATP+KLA
 NM_008386 insulin I (Ins1), mRNA [NM_008386] KLA 1.00 .99 .99 1.03 1.01 .98 1.06
ATP .97 1.03 1.00 1.03 .99 1.07 1.05
KLA/ATP 1.03 .93 .98 1.04 1.07 1.03 1.01
Ins2
KLA  ATP  ATP+KLA
 NM_008387 insulin II (Ins2), mRNA [NM_008387] KLA .99 1.00 1.00 1.01 1.00 1.02 1.00
ATP 1.01 .99 1.00 1.00 .98 .99 1.01
KLA/ATP .99 1.01 1.00 .98 .99 .99 .98
Insrr
KLA  ATP  ATP+KLA
 NM_011832 insulin receptor-related receptor (Insrr), mRNA [NM_011832] KLA 1.11 1.18 1.18 1.17 1.16 1.19 1.16
ATP .93 .91 1.08 1.07 1.21 1.11 .99
KLA/ATP 1.09 1.14 1.16 1.13 1.15 1.19 1.03
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Lef1
KLA  ATP  ATP+KLA
 NM_010703 lymphoid enhancer binding factor 1 (Lef1), mRNA [NM_010703] KLA 1.00 1.05 1.00 1.05 1.01 1.07 1.07
ATP .96 .98 1.03 1.09 .99 1.04 1.00
KLA/ATP 1.02 .98 .95 1.08 1.02 1.16 1.08
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mdm2
KLA  ATP  ATP+KLA
 NM_010786 transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA [NM_010786] KLA 1.77 1.59 1.98 1.51 1.77 1.60 1.77
ATP 1.01 1.21 1.36 3.24 5.04 2.08 1.36
KLA/ATP 1.89 1.86 2.93 5.65 5.98 2.78 2.64
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.27304
9
KLA  ATP  ATP+KLA
 119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.27574
2
KLA  ATP  ATP+KLA
 112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.30793
2
KLA  ATP  ATP+KLA
 160333363 Unknown KLA .13 .12 .14 .16 .15 .18 .15
ATP .92 .94 1.12 .93 .58 .29 .31
KLA/ATP .11 .11 .18 .20 .28 .20 .19
Mm.4387
KLA  ATP  ATP+KLA
 133892666 Unknown KLA .85 .87 .85 .89 .77 .91 1.18
ATP 1.01 1.01 .87 1.07 .75 .86 .93
KLA/ATP .88 .86 .77 .81 .72 .91 .84
Mm.47351
0
KLA  ATP  ATP+KLA
 162287332 Unknown KLA 4.46 4.82 5.29 4.00 2.26 1.25 1.10
ATP 1.24 1.72 1.02 2.08 1.66 2.53 .55
KLA/ATP 6.11 7.67 4.29 6.99 3.11 2.86 2.30
Nfkb1
KLA  ATP  ATP+KLA
 BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
 M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Nfkbia
KLA  ATP  ATP+KLA
 NM_010907 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] KLA 18.65 18.46 13.63 17.88 14.25 9.17 7.92
ATP .91 1.09 7.11 32.39 17.44 10.49 1.72
KLA/ATP 15.57 17.66 15.73 23.91 13.83 10.73 9.48
Nkx3-1
KLA  ATP  ATP+KLA
 NM_010921 NK-3 transcription factor, locus 1 (Drosophila) (Nkx3-1), mRNA [NM_010921] KLA .91 .98 1.06 .98 1.01 1.02 1.08
ATP 1.03 .94 1.07 1.12 .97 1.03 1.04
KLA/ATP 1.04 1.01 1.01 1.05 1.04 1.12 .95
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pdgfa
KLA  ATP  ATP+KLA
 NM_008808 platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] KLA .63 .56 .42 .34 .31 .33 .52
ATP .89 .80 .69 1.23 5.97 3.99 2.73
KLA/ATP .64 .53 .43 .77 3.48 3.78 2.37
Pdgfb
KLA  ATP  ATP+KLA
 NM_011057 platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] KLA .45 .43 .38 .46 .69 .48 .58
ATP .94 .95 .66 .74 .67 .77 1.06
KLA/ATP .43 .43 .37 .39 .52 .55 1.64
Pdgfc
KLA  ATP  ATP+KLA
 AK081347 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130008P20 product:platelet-derived growth factor, C polypeptide, full insert sequence. [AK081347] KLA .93 1.07 1.00 1.03 .93 .95 .98
ATP 1.05 1.04 .94 1.02 1.04 1.00 1.05
KLA/ATP 1.06 1.02 .99 .96 .99 1.05 1.01
Pdgfc
KLA  ATP  ATP+KLA
 NM_019971 platelet-derived growth factor, C polypeptide (Pdgfc), mRNA [NM_019971] KLA 1.56 1.52 1.84 2.08 1.83 1.33 .79
ATP .98 .91 .86 .91 .78 1.43 3.28
KLA/ATP 1.45 1.50 1.25 1.73 1.99 1.56 1.12
Pdgfd
KLA  ATP  ATP+KLA
 AK141551 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630020I23 product:platelet-derived growth factor, D polypeptide, full insert sequence [AK141551] KLA 1.07 1.01 1.06 .98 .94 1.00 1.00
ATP .98 .99 1.10 1.00 .96 1.00 .94
KLA/ATP 1.00 1.03 1.05 1.02 .94 .97 1.03
Pdgfd
KLA  ATP  ATP+KLA
 NM_027924 platelet-derived growth factor, D polypeptide (Pdgfd), mRNA [NM_027924] KLA .99 .93 .95 .97 1.00 .99 .95
ATP 1.01 .99 1.00 .93 1.05 1.04 1.06
KLA/ATP .91 .91 .96 .92 .92 .99 1.05
Pdgfra
KLA  ATP  ATP+KLA
 NM_011058 platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] KLA 1.02 1.05 1.02 1.01 1.03 1.03 1.01
ATP 1.01 1.02 1.03 1.04 1.00 1.01 1.01
KLA/ATP 1.01 1.01 .99 1.03 1.02 1.03 1.01
Pdgfrb
KLA  ATP  ATP+KLA
 NM_008809 platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] KLA 4.85 5.49 4.56 3.94 3.71 2.05 1.51
ATP .99 1.00 1.11 1.27 1.02 1.83 1.23
KLA/ATP 5.09 5.86 4.30 2.51 1.74 1.84 3.23
Pdpk1
KLA  ATP  ATP+KLA
 NM_011062 3-phosphoinositide dependent protein kinase-1 (Pdpk1), transcript variant 1, mRNA [NM_011062] KLA .90 .90 .84 1.00 1.32 1.19 1.15
ATP 1.05 1.09 1.04 1.14 1.31 .97 1.17
KLA/ATP .90 .89 .91 1.02 1.27 .96 1.42
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Pten
KLA  ATP  ATP+KLA
 NM_008960 phosphatase and tensin homolog (Pten), mRNA [NM_008960] KLA .79 .73 .61 .59 .56 .70 1.00
ATP 1.04 1.11 1.07 1.12 1.03 1.38 .83
KLA/ATP .75 .69 .60 .74 .93 1.09 1.24
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rb1
KLA  ATP  ATP+KLA
 NM_009029 retinoblastoma 1 (Rb1), mRNA [NM_009029] KLA .67 .60 .55 .51 .46 .75 .79
ATP 1.04 1.01 1.12 .86 .59 .43 .76
KLA/ATP .64 .59 .58 .46 .36 .30 .65
Rela
KLA  ATP  ATP+KLA
 NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Srd5a2
KLA  ATP  ATP+KLA
 NM_053188 steroid 5 alpha-reductase 2 (Srd5a2), mRNA [NM_053188] KLA 1.01 1.01 1.02 1.02 .98 1.00 1.02
ATP 1.01 .92 1.04 1.07 1.01 1.02 .94
KLA/ATP 1.04 1.02 1.03 1.02 .98 1.16 1.01
Tcf3
KLA  ATP  ATP+KLA
 NM_001079822 transcription factor 3 (Tcf3), transcript variant 1, mRNA [NM_001079822] KLA 1.03 .98 1.01 .98 .98 1.03 1.01
ATP 1.00 1.02 1.00 1.06 1.10 1.07 .99
KLA/ATP 1.07 .99 .97 1.05 1.05 1.11 .96
Tcf7
KLA  ATP  ATP+KLA
 NM_009331 transcription factor 7, T-cell specific (Tcf7), mRNA [NM_009331] KLA 1.00 1.01 1.03 1.00 .98 1.01 1.07
ATP .99 .98 1.02 1.03 1.03 1.00 1.01
KLA/ATP 1.00 1.03 1.04 1.02 1.04 1.02 1.00
Tcf7l2
KLA  ATP  ATP+KLA
 NM_009333 transcription factor 7-like 2, T-cell specific, HMG-box (Tcf7l2), mRNA [NM_009333] KLA 1.01 1.12 1.11 1.31 1.06 1.34 1.29
ATP 1.04 1.05 .94 1.06 .90 .81 .96
KLA/ATP 1.08 1.11 1.05 1.18 1.04 1.02 1.42
Tgfa
KLA  ATP  ATP+KLA
 NM_031199 transforming growth factor alpha (Tgfa), mRNA [NM_031199] KLA 1.01 .99 1.00 1.03 1.01 1.04 1.04
ATP 1.01 1.04 1.02 1.02 1.02 1.01 1.05
KLA/ATP 1.01 1.02 1.02 1.02 1.02 1.06 1.02
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74